fan li

Quick facts

Phase 2 pipeline

• AK112 with SCRT · Unknown
  AK112 with SCRT is a small molecule that targets the molecular target to exert its therapeutic effect.
• AK112 with SCRT and CapeOX · Oncology
  AK112 is a bispecific antibody that simultaneously engages PD-1 and LAG-3 to enhance anti-tumor immune responses, combined with chemotherapy (capecitabine and oxaliplatin) to treat solid tumors.
• Terelizumab · Other

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• fan li portfolio CI brief
• fan li pipeline updates RSS